Clinical Trial: A Study to Evaluate ENERGI-F703EB Cream in Epidermolysis Bullosa

U.S., Oct. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07858422) titled 'A Study to Evaluate ENERGI-F703EB Cream in Epidermolysis Bullosa' on Aug. 20.

Brief Summary: This is a phase II, intra-subject randomized, double-blind, vehicle-controlled, parallel, multicenter study to evaluate the safety and preliminary efficacy of ENERGI-F703EB Cream in subjects who are >= 18 years old with epidermolysis bullosa simplex (EBS), junctional epidermolysis bullosa (JEB), or dystrophic epidermolysis bullosa (DEB). In total, approximately 24 subjects will be enrolled from multiple sites in Taiwan. The study duration per subject is approximately 16 weeks; which includes a 2 to 4-week period between Visit 1 and Visit 2 fo...